Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IGC Pharma, Inc. Director's Dealing 2021

Dec 23, 2021

34705_dirs_2021-12-23_b7b12e12-e0b3-48f9-9acd-023c8435ecdd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: India Globalization Capital, Inc. (IGC)
CIK: 0001326205
Period of Report: 2021-12-20

Reporting Person: MUKUNDA RAM (Director, CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-20 Common Stock A 0 $0.0 Acquired 2174760 Direct
2021-12-20 Common Stock A 0 $0.0 Acquired 727417 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-12-20 Restricted Stock Units $0.0 A 1000000 Acquired 2024-04-01 Common Stock (1000000) Direct
2021-12-20 Restricted Stock Units $0.0 A 3200000 Acquired Common Stock (3200000) Direct
2021-12-20 Restricted Stock Units $0.0 A 50000 Acquired 2024-04-01 Common Stock (50000) Indirect

Footnotes

F1: RSUs subject to vesting equally over three years starting on March 31, 2022.

F2: Corrects a previous Section 16 May 14, 2021, filing, which overstated the ownership of non-derivative securities by 1,000,000 shares.

F3: RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs do not have an exercisable or expiration date. The RSUs vest when milestones are achieved.

F4: RSUs subject to vesting equally over three years starting on March 31, 2022.

F5: Corrects a previous Section 16 May 14, 2021, filing, which overstated the ownership of non-derivative securities by 50,000 shares